Showing Pathways for query: 'second dose'
Searched: in measures.
||Risk Practice The risks and challenges of the global COVID-19- vaccine rollout A realistic assessment of the heroic effort to administer billions of doses of COVID-19 vaccines to an agonized global population is necessary the stakes could not be higher. This article was a collaborative effort by the global Risk Practice and authors from across the firm, including Gaurav Agrawal, Tara Azimi, Jennifer Heller, Pooja Kumar, Mihir Mysore, Parag Patel, Adam Sabow, Shubham Singhal, and Joseph Truesdale||McKinsey||, vaccines to an agonized , vaccine , united states , vaccines , risks , doses , challenges , vaccine doses , global , critical risk areas , risk , centers for disease control , administration , states , vaccine deployment , united , critical risk , manufacturers , production , risk areas , disease||31-Jan-2021||auto-generated|
||Healthcare Systems & Services Practice When will the COVID-19 pandemic end? An update This article updates our earlier perspectives on when the coronavirus pandemic will end. Transition toward normalcy in the United States remains most likely in the second quarter of 2021 and herd immunity in the third and fourth quarters, but the emergence of new strains and a slow start to vaccine rollout raise real risks to both timelines. We also add a perspective for the United Kingdom. by Sarun Charumilind||McKinsey||, immunity in the united , united states , herd immunity , united kingdom , united , immunity , herd , achieve herd immunity , vaccine , states , united kingdom and united , herd immunity more-infectious strains , united states increase , united states or united , united states remains , vaccines ,||31-Jan-2021||auto-generated|